IRhythm Technologies Inc. $(IRTC)$ has announced the results from two significant real-world studies at the American Diabetes Association's 85th Scientific Sessions (ADA 2025) in San Francisco. The studies focused on cardiac arrhythmias in patients with type 2 diabetes, some of whom also have chronic kidney disease. The findings indicate that cardiac arrhythmias are common and often occur early in these patients, frequently preceding major cardiovascular events. The analyses utilized longitudinal claims data from over 30 million U.S. adults, highlighting the potential for enhanced early detection strategies in at-risk populations. These results underscore the importance of monitoring patients based on unique risk factors rather than symptoms alone, as many arrhythmias are asymptomatic.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.